Significance of Caveolin-1 Regulators in Pancreatic Cancer

Chen, Tao; Liu, Liang; Xu, Hua; Wang, Wen Quan; Wu, Chun; Yao, Weichao; Lei, Yu

doi:10.7314/apjcp.2013.14.8.4501

Cited by 8 publications

(9 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The examples of pathways activated in non-genomic way are Src/Raf-1/ERK2 pathway or kinases like PI3K or Akt that have influence on phosphorylation and activation of AR [61]. It was noticed that in other cancers like pancreatic cancer CAV1 acts as a regulator of carcinogenesis [59]. In some cases, CAV1 is capable of inhibiting cancer development, while, more frequently, it is related to malignancy [62,63].…”

Section: Caveolinmentioning

confidence: 98%

See 1 more Smart Citation

The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer

Matysiak

Ochędalski

Piastowska-Ciesielska

2014

Gynecological Endocrinology

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most common gynecological malignancy. Alterations of angiogenic factors including angiotensin (AngII) or VEGF are observed in EC. Expression of angiotensin receptor 1 (AT1) is correlated with EC. Moreover, the expression of VEGF is up-regulated by AngII. Androgens are involved in the pathogenesis of EC. Genetic variations in androgen receptor (AR) gene may increase EC risk. This review proved strong correlation among EC, AngII, its receptors and AR, where AT influence on AR and, as a result, induce the expression of genes related to carcinogenesis.

show abstract

Section: Caveolinmentioning

confidence: 98%

“…Caveolae are structures that consist of cholesterols and sphingolipids. They are present in endothelia, muscle cells, and lung epithelial cells [59]. CAV1 is correlated with prostate cancer.…”

Section: Caveolinmentioning

confidence: 99%

The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer

Matysiak

Ochędalski

Piastowska-Ciesielska

2014

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…In pancreatic cancer cells, p53 along with the transcription factors E2F/DP-1 and Sp1 directly bind to the caveolin-1 promoter to induce expression [11]. Higher expression is also correlated with advanced pathologic stage and poor prognosis of prostate cancer [11], pulmonary squamous cell [12] and renal cell carcinomas [13]. Despite the function of CAV1 as both tumour suppressor and an oncogene, the molecular determinants that allow one role to prevail over the other remain essentially undefined [1].…”

Section: Introductionmentioning

confidence: 97%

“…In addition, the PKCɛ/MEK/ c-Myc signaling also regulates CAV1 in prostate cancer cells (3). In pancreatic cancer cells, p53 along with the transcription factors E2F/DP-1 and Sp1 directly bind to the caveolin-1 promoter to induce expression [11]. Higher expression is also correlated with advanced pathologic stage and poor prognosis of prostate cancer [11], pulmonary squamous cell [12] and renal cell carcinomas [13].…”

Section: Introductionmentioning

confidence: 98%

Caveolin-1 is transcribed from a hypermethylated promoter to mediate colonocyte differentiation and apoptosis

Dasgupta

Thakur

et al. 2015

Experimental Cell Research

View full text Add to dashboard Cite

“…45 Transmembrane scaffolding proteins belonging to the caveolin family then mediate transcytosis of nab-paclitaxel across the endothelial cell into the peritumor interstitium. 46,47 Due to the specific …”

Section: Preclinical Evidencementioning

confidence: 99%

Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma

Narayanan¹,

Weekes

2015

GICTT

View full text Add to dashboard Cite

Pancreatic adenocarcinoma is a leading cause of cancer-related mortality worldwide, and surgical resection offers the only chance of cure. Since the majority of patients have unresectable disease at presentation, the emphasis has been on identifying effective chemotherapy regimens to prolong survival and control tumor burden. Gemcitabine has been the cornerstone of treatment ever since it was discovered to be an active agent in advanced pancreatic cancer nearly two decades ago, but the overall prognosis in patients with metastatic disease remains dismal. A dense fibrotic stroma around the tumor devoid of vasculature and the resultant hypoxic tumor microenvironment are implicated in the chemotherapy-resistant nature of this malignancy. In recent years, a growing body of literature has further elucidated several aspects of pancreatic tumor biology, such as its ability to utilize albumin from the peritumoral tissues to support its metabolic needs. High-pressure homogenization of paclitaxel with nanoparticle albumin results in the formation of soluble 130 nm complexes with albumin acting as the carrier for the otherwise hydrophobic paclitaxel. Once these complexes reach the tumor milieu, they act by depleting the tumor stroma. In addition, paclitaxel is also transported into the tumor cell along with albumin, where it then exerts its antineoplastic activity. Nanoparticle albuminbound (nab)-paclitaxel also increases gemcitabine levels inside the tumor cells by inhibiting cytidine deaminase, the enzyme that degrades gemcitabine. This review focuses on proposed mechanisms of efficacy of nab-paclitaxel in pancreatic cancer and discusses the preclinical and clinical studies of relevance.

show abstract

Significance of Caveolin-1 Regulators in Pancreatic Cancer

Cited by 8 publications

References 91 publications

The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer

The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer

Caveolin-1 is transcribed from a hypermethylated promoter to mediate colonocyte differentiation and apoptosis

Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma

Contact Info

Product

Resources

About